In a report released today, Juan C. Sanabria from BMO Capital maintained a Buy rating on Ventas (VTR – Research Report), with a price target of $57.00. The company’s shares closed last Thursday at $50.87.
According to TipRanks.com, Sanabria is a 2-star analyst with an average return of 0.3% and a 45.9% success rate. Sanabria covers the Financial sector, focusing on stocks such as Retail Opportunity Investments, National Storage Affiliates, and Phillips Edison & Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ventas with a $60.33 average price target, representing a 17.0% upside. In a report issued on July 25, Barclays also maintained a Buy rating on the stock with a $65.00 price target.
Based on Ventas’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.02 billion and net profit of $38.73 million. In comparison, last year the company earned revenue of $910 million and had a GAAP net loss of $57.21 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ventas, Inc. engages in the acquisition and ownership of seniors housing and healthcare properties. The company invests in seniors housing and healthcare properties through acquisitions and leases its properties to unaffiliated tenants or operate them through independent third-party managers. It operates through the following segments: Triple-Net Leased Properties, Senior Living Operations, and Office Operations. The company was founded in 1983 and is headquartered in Chicago, IL.
Read More on VTR:
- Crown Point’s Subsidiary Files Prospectus Supplement and Launches Debt Offering in Argentina
- Alexco Announces the Filing of Management Information Circular in Connection with Special Meeting to Approve Acquisition by Hecla
- Icahn Enterprises L.P. Reports Second Quarter 2022 Financial Results
- CHESSWOOD ANNOUNCES SECOND QUARTER 2022 RESULTS
- Needham Thinks Generation Bio’s Stock is Going to Recover